EGFR and lung carcinoma: Taken together with our findings that mutant EGFR-dependent cells die via the intrinsic pathway of apoptosis, we hypothesized that the intrinsic pathway could be manipulated by ABT-737 to enhance erlotinib-induced cell killing of EGFR mutant lung cancer cells.